# Safety and Tolerability of the Japanese Encephalitis Vaccine IC51

> **NCT00605085** · PHASE3 · COMPLETED · sponsor: **Valneva Austria GmbH** · enrollment: 2675 (actual)

## Conditions studied

- Japanese Encephalitis

## Interventions

- **BIOLOGICAL:** Japanese Encephalitis purified inactivated vaccine (IC51)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00605085
- **Lead sponsor:** Valneva Austria GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** —
- **Final completion:** 2006-11
- **Target enrollment:** 2675 (ACTUAL)
- **Last updated:** 2024-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00605085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00605085, "Safety and Tolerability of the Japanese Encephalitis Vaccine IC51". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00605085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*